Hodgkin lymphoma autologous dhap
NettetSalar A, Martino R, Perea G, Ribera JM, Lopez-Guillermo A, Guardia R, et al. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, … NettetIn a review in 1993, Vose commented that DHAP followed by high dose chemotherapy and autologous haemopoietic stem cell transplant was then the standard of care for …
Hodgkin lymphoma autologous dhap
Did you know?
Nettet3. mar. 2024 · LyMA trial has demonstrated the benefit of rituximab maintenance after autologous stem cell transplantation (ASCT) in previously untreated mantle-cell lymphoma patients (MCL). Induction consisted ... Nettet27. jun. 2024 · Investigator's choice of platinum-based immunochemotherapy (ie. R-ICE, R-GemOx, R-GDP, R-DHAP)+ High dose chemotherapy (ie. BEAM) + autologous HSCT. *Ibrutinib or lenalidomide may be used in patients who are no longer eligible for autologous HSCT after 2 cycles of immunochemotherapy
Nettet17. mar. 2024 · Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with … Nettet10. des. 2024 · Although most patients with cHL are cured with initial chemotherapy, up to 20% to 25% of patients will relapse or have primary refractory (R/R) disease. 1 While high-dose therapy and an auto-HCT consolidation can cure cHL patients responding to subsequent treatments, only about half of these patients will attain durable disease …
NettetThe DHAP regimen (high-dose cytarabine in combination with dexamethasone and cisplatin) with or without rituximab (DHAP+/-R) is one of the most common regimens in daily practice. It is considered the standard treatment for relapse or refractory Hodgkin's and non-Hodgkin's lymphoma (NHL). Cisplatin n … Nettet21. apr. 2011 · Relapsed or refractory Hodgkin lymphoma is a challenging problem for clinicians who treat hematologic malignancies. The standard management of these …
Nettet10. des. 2024 · Approximately 10% to 30% of patients with classical Hodgkin lymphoma (cHL) develop relapsed or refractory (R/R) disease. Of those patients, ... 73% vs 86% …
NettetSession title: Hodgkin lymphoma - Clinical. Background Immunotherapy with checkpoint inhibitors (anti-PD-1) is highly effective in relapsed/refractory (R/R) … pound cake berry trifleNettetHigh-dose therapy and autologous stem cell transplantation is a potential curative approach for these patients. The primary aim of second-line therapy is the attainment of … tour of riu bahamasNettet26. jul. 2010 · Purpose Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. Patients and Methods Patients with CD20+ … pound cake batter consistencyNettetAchieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose … tour of river rough ford plantNettetHigh-dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT) is a standard of care for patients with relapsed Hodgkin lymphoma. Different conditioning regimens before AHSCT have been used, with the 2 most common being BEAM (carmustine, etoposide, cytarabine, and melphalan) and BUCYVP16 (busulfan, … pound cake betty crockerNettetPatients and methods: In this retrospective analysis, 53 patients with primary refractory or relapsed Hodgkin's disease (HD) (n = 13) or non-Hodgkin lymphoma (NHL) (n = 40) … pound cake berriesNettetIntroduction. Autologous peripheral blood stem cell transplantation (APBSCT) has been widely used in the treatment of hematologic and solid tumours and autoimmune … pound cake beauty